Amer Zeidan, Professor of Medicine, Chief of Hematologic Malignancies, Director of Heme Clinical Research at Yale University, shared a post on LinkedIn:
“A moment of pride!
A co-first author in the best scientific journal in medicine for a clinical trial that resulted in FDA approval in the USA and is changing how we treat acute myeloid leukemia. Congratulations to all the authors and everyone who contributed to the study’s success especially patients and their families.”
Title: All-Oral Treatment of Newly Diagnosed Acute Myeloid Leukemia
Authors: Gail J. Roboz, Amer M. Zeidan, Gabriel N. Mannis, Pau Montesinos, Montserrat Arnan, Michael R. Savona, Olatoyosi Odenike, James K. McCloskey, Harshad V. Amin, Amir T. Fathi, Teresa Bernal del Castillo, Gabriela Rodríguez-Macías, Jane L. Liesveld, Annie P. Im, Jan Cerny, Teresa C. Gentile, Aram Oganesian, Danna Chan, Yubing Wan, Margit Dijkstra, Harold N. Keer, Elizabeth A. Griffiths, Courtney D. DiNardo
Other articles featuring Amer Zeidan on OncoDaily.